苏利股份：苏利制药板块目前主要从事医药中间体研发及生产

Group 1 - The core viewpoint of the article is that Suli Co., Ltd. (603585) is currently facing losses in its pharmaceutical intermediate segment due to various factors such as market competition and the overall economic environment [1] - The company plans to enhance its management level, reduce costs internally, and expand its market externally to improve its performance and create greater value for shareholders [1]